பெர்ன்ஹார்ட் ஸ்கிமிட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பெர்ன்ஹார்ட் ஸ்கிமிட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பெர்ன்ஹார்ட் ஸ்கிமிட் Today - Breaking & Trending Today

Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With .
Polyphor AGJune 28, 2021 GMT
Co-primary endpoint of the study objective response rate (ORR) was not met
The board of directors is undergoing a strategic assessment regarding the future of the company
ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) Polyphor AG (SIX: POLN), a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint. ....

Switzerland General , Hernan Levett , Bernhard Schmid , Guillaume Van Renterghem , Polyphor Ltd , Swiss Exchange , Outer Membrane Protein Targeting Antibiotics , ஹெர்னான் லெவெட் , பெர்ன்ஹார்ட் ஸ்கிமிட் , சுவிஸ் பரிமாற்றம் ,

Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients with advanced

Polyphor AG / Key word(s): Study results28-Jun-2021 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, June 28, 2021Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients. ....

Switzerland General , Hernan Levett , Bernhard Schmid , Guillaume Van Renterghem , Polyphor Ltd , Swiss Exchange , Outer Membrane Protein Targeting Antibiotics , ஹெர்னான் லெவெட் , பெர்ன்ஹார்ட் ஸ்கிமிட் , சுவிஸ் பரிமாற்றம் ,

Polyphor to Present at the UBS Global Healthcare Virtual

About Polyphor
Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, p ....

Switzerland General , Gokhan Batur , Hernan Levett , Mary Ann Chang , Bernhard Schmid , Polyphor Ltd , Swiss Exchange , Healthcare Virtual Conference , Wednesday May , Outer Membrane Protein Targeting Antibiotics , சுவிட்சர்லாந்து ஜநரல் , ஹெர்னான் லெவெட் , மேரி ஆண்டு சாங் , பெர்ன்ஹார்ட் ஸ்கிமிட் , சுவிஸ் பரிமாற்றம் , சுகாதாரம் மெய்நிகர் மாநாடு , புதன்கிழமை இருக்கலாம் ,

Polyphor to present at the UBS Global Healthcare Virtual Conference

Polyphor to present at the UBS Global Healthcare Virtual Conference
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Switzerland General , Gokhan Batur , Hernan Levett , Mary Ann Chang , Bernhard Schmid , Polyphor Ltd , Swiss Exchange , Healthcare Virtual , Healthcare Virtual Conference , Wednesday May , Outer Membrane Protein Targeting Antibiotics , ஹெர்னான் லெவெட் , மேரி ஆண்டு சாங் , பெர்ன்ஹார்ட் ஸ்கிமிட் , சுவிஸ் பரிமாற்றம் , சுகாதாரம் மெய்நிகர் , சுகாதாரம் மெய்நிகர் மாநாடு , புதன்கிழமை இருக்கலாம் ,

EQS-Adhoc: Polyphor AG: Polyphor Annual General Meeting 2021

EQS-Adhoc: Polyphor AG: Polyphor Annual General Meeting 2021
Polyphor Annual General Meeting 2021
06-Apr-2021 / 19:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, April 6, 2021
Polyphor Annual General Meeting 2021
Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the 24
th Annual General Meeting (AGM) with a significant majority, with the exception of the proposed increase of the conditional capital for the employee stock option plan (ESOP), which did not receive the required two thirds majority. In line with the COVID-19 Ordinance 2 of the Swiss Federal Council, no shareholders were allowed to attend the AGM in person. The independent proxy represented 47.7 percent of the company s shares. ....

Switzerland General , Mary Ann Chang , Bernhard Schmid , Bernard Bollag , Hugh Odowd , Hernan Levett , Andreas Walln , Silvio Inderbitzin , Kuno Sommer , Swiss Federal Council , Group News Service , Eqs Group , Polyphor Ltd , Swiss Exchange , Annual General Meeting , Hugho Dowd , Outer Membrane Protein Targeting Antibiotics , சுவிட்சர்லாந்து ஜநரல் , மேரி ஆண்டு சாங் , பெர்ன்ஹார்ட் ஸ்கிமிட் , ஹக் ஓதோவ்த் , ஹெர்னான் லெவெட் , குனோ சோமர் , சுவிஸ் கூட்டாட்சியின் சபை , குழு செய்தி சேவை , ஈக்ஸ் குழு ,